Abstract 1639P
Background
Electronic Medical Records (EMR) and administrative claims (AC) are non-negligible source of information for the constitution of observational databases, a fundamental source of information in rare cancers. Pleural Mesothelioma (PM) is a rare cancer with a dismal prognosis. Despite the progresses in the cure achieved in the last years, only few therapeutic options are currently available. Hereby we describe the constitution process of a EHDEN (European Health Data Excellence Network) database for PM in a center at high volume for PM.
Methods
Patients (pts) diagnosed with PM and who underwent at least one procedure (either diagnostic or therapeutic) at Azienda Ospedaliera SS Antonio e Biagio in Alessandria (AOAL), were identified using a code-identification system based on ICD 9 CM code 163 specific for PM. Data regarding demographics, histology and clinical course were obtained from electronic medical records. Data regarding procedures were obtained through AC. An extraction transform load (ETL) process was structured through data ingestion, data lake configuration and data mapping execution. Data retrieved were standardized to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). The database obtained, as well as the ETL process are monthly updated and implemented. The process was validated by the EHDEN consortium.
Results
867 PM pts, diagnosed from 01/2016 to 11/2021, have been identified at AOAL using the ETL procedure tied to EHDEN consortium. Data have been provided in a readily exploitable OMOP CDM format. In the same period from our internal research records we identified 594 patients (68% of the whole number of PM patients accessing AOAL).
Conclusions
We demonstrate that data retrieval from both AC and EMR of PM pts is feasible at a single institution at high volume for PM, with standardization to the OMOP CDM. The ETL procedures allowed the identification of additional cases. Our results pave the way to novel collaborative networks in PM, crucial for large scale observational studies and translational research. The ETL process starting from EMR and AC is applicable also to other rare cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
EHDEN (European Health Data Excellence Network).
Disclosure
M. Venturelli, A. Mazzucco: Financial Interests, Personal, Full or part-time Employment: Reply. All other authors have declared no conflicts of interest.